Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers.  

The company says that more than half of the patients planned for the study have already been enrolled, with the trial continuing to progress through dose escalation. 

The advancement of ONA-255 represents an important milestone for Ona following its $86.6 million Series B financing earlier this year and forms part of the company’s broader strategy to build a differentiated pipeline of ADCs targeting treatment-resistant cancer biology.  

Alongside ONA-255, Ona is advancing ONA-389, a first-in-class ADC in development for colorectal cancer and hepatocellular carcinoma. ONA-389 is progressing through IND-enabling studies and is expected to enter the clinic in the second half of 2027.

The company is also advancing ONA-418, the third programme in its ADC portfolio, which incorporates dual-linker, dual-payload technology designed to further expand the potential of Ona’s ADC pipeline. 

To support the advancement of its pipeline, Ona has appointed Aleix Prat as Chief Medical Officer. He is Director of the Clínic Barcelona Comprehensive Cancer Center, Professor of Medicine at the University of Barcelona, Co-Founder of Reveal Genomics and author of more than 350 peer-reviewed publications. 

“This has been a transformational year for Ona. Advancing ONA-255 into the clinic and achieving rapid enrolment in our Phase Ia study represent important milestones for the company,” said Valerie Vanhooren, Co-Founder and Chief Executive Officer of Ona Therapeutics. “Aleix brings exceptional clinical, translational and drug development expertise that will be instrumental as we advance ONA-255 and our broader ADC pipeline. These achievements reflect years of work building our discovery platform and establishing a differentiated pipeline of programs designed to address treatment-resistant cancer biology.”